230 related articles for article (PubMed ID: 23343767)
21. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
[TBL] [Abstract][Full Text] [Related]
22. Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome.
Roy A; Roberts I; Vyas P
Semin Fetal Neonatal Med; 2012 Aug; 17(4):196-201. PubMed ID: 22421527
[TBL] [Abstract][Full Text] [Related]
23. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome.
Malinge S; Izraeli S; Crispino JD
Blood; 2009 Mar; 113(12):2619-28. PubMed ID: 19139078
[TBL] [Abstract][Full Text] [Related]
24. GATA1s goes germline.
Mundschau G; Crispino J
Nat Genet; 2006 Jul; 38(7):741-2. PubMed ID: 16804537
[No Abstract] [Full Text] [Related]
25. [Myeloid proliferations related to Down syndrome].
Hasegawa D
Rinsho Ketsueki; 2019; 60(9):1299-1307. PubMed ID: 31597856
[TBL] [Abstract][Full Text] [Related]
26. Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing.
Terui K; Toki T; Taga T; Iwamoto S; Miyamura T; Hasegawa D; Moritake H; Hama A; Nakashima K; Kanezaki R; Kudo K; Saito AM; Horibe K; Adachi S; Tomizawa D; Ito E
Genes Chromosomes Cancer; 2020 Mar; 59(3):160-167. PubMed ID: 31606922
[TBL] [Abstract][Full Text] [Related]
27. A novel mutation in the GATA1 gene associated with acute megakaryoblastic leukemia in a Korean Down syndrome patient.
Kim IS; Park ES; Lim JY; Ki CS; Chi HS
J Korean Med Sci; 2008 Dec; 23(6):1105-8. PubMed ID: 19119459
[TBL] [Abstract][Full Text] [Related]
28. Presentation of Acute Megakaryoblastic Leukemia Associated with a GATA-1 Mutation Mimicking the Eruption of Transient Myeloproliferative Disorder.
Boos MD; Wine Lee L; Freedman JL; Novoa RA; Chu EY; Perman MJ
Pediatr Dermatol; 2015; 32(5):e204-7. PubMed ID: 26205501
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome.
Watanabe K
Pediatr Int; 2019 Mar; 61(3):222-229. PubMed ID: 30593694
[TBL] [Abstract][Full Text] [Related]
30. Clonal selection in xenografted TAM recapitulates the evolutionary process of myeloid leukemia in Down syndrome.
Saida S; Watanabe K; Sato-Otsubo A; Terui K; Yoshida K; Okuno Y; Toki T; Wang R; Shiraishi Y; Miyano S; Kato I; Morishima T; Fujino H; Umeda K; Hiramatsu H; Adachi S; Ito E; Ogawa S; Ito M; Nakahata T; Heike T
Blood; 2013 May; 121(21):4377-87. PubMed ID: 23482930
[TBL] [Abstract][Full Text] [Related]
31. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
[TBL] [Abstract][Full Text] [Related]
32. Transient abnormal myelopoiesis of a newborn not associated with chromosome 21 abnormalities or GATA1 mutations.
Nakashima MO; Shetty S; Chicka M; Flagg A; Eng C; Cotta CV
Pediatr Blood Cancer; 2015 Feb; 62(2):353-355. PubMed ID: 25175265
[TBL] [Abstract][Full Text] [Related]
33. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.
Malinge S; Bliss-Moreau M; Kirsammer G; Diebold L; Chlon T; Gurbuxani S; Crispino JD
J Clin Invest; 2012 Mar; 122(3):948-62. PubMed ID: 22354171
[TBL] [Abstract][Full Text] [Related]
34. Leukemogenesis in infants and young children with trisomy 21.
Roberts I
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):1-8. PubMed ID: 36485097
[TBL] [Abstract][Full Text] [Related]
35. Down syndrome and GATA1-related transient leukemia.
Sandoval C; Pine SR
J Pediatr; 2007 Mar; 150(3):e34. PubMed ID: 17307526
[No Abstract] [Full Text] [Related]
36. The landscape of somatic mutations in Down syndrome-related myeloid disorders.
Yoshida K; Toki T; Okuno Y; Kanezaki R; Shiraishi Y; Sato-Otsubo A; Sanada M; Park MJ; Terui K; Suzuki H; Kon A; Nagata Y; Sato Y; Wang R; Shiba N; Chiba K; Tanaka H; Hama A; Muramatsu H; Hasegawa D; Nakamura K; Kanegane H; Tsukamoto K; Adachi S; Kawakami K; Kato K; Nishimura R; Izraeli S; Hayashi Y; Miyano S; Kojima S; Ito E; Ogawa S
Nat Genet; 2013 Nov; 45(11):1293-9. PubMed ID: 24056718
[TBL] [Abstract][Full Text] [Related]
37. Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.
Ono R; Hasegawa D; Hirabayashi S; Kamiya T; Yoshida K; Yonekawa S; Ogawa C; Hosoya R; Toki T; Terui K; Ito E; Manabe A
Eur J Pediatr; 2015 Apr; 174(4):525-31. PubMed ID: 25266042
[TBL] [Abstract][Full Text] [Related]
38. Enigma of myeloid proliferation in Down syndrome.
Hasegawa D
Pediatr Int; 2019 Mar; 61(3):221. PubMed ID: 30916856
[No Abstract] [Full Text] [Related]
39. Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome.
Yamato G; Deguchi T; Terui K; Toki T; Watanabe T; Imaizumi T; Hama A; Iwamoto S; Hasegawa D; Ueda T; Yokosuka T; Tanaka S; Yanagisawa R; Koh K; Saito AM; Horibe K; Hayashi Y; Adachi S; Mizutani S; Taga T; Ito E; Watanabe K; Muramatsu H
Leukemia; 2021 May; 35(5):1480-1484. PubMed ID: 33654203
[No Abstract] [Full Text] [Related]
40. Down syndrome-related transient abnormal myelopoiesis is attributed to a specific erythro-megakaryocytic subpopulation with
Nishinaka-Arai Y; Niwa A; Matsuo S; Kazuki Y; Yakura Y; Hiroma T; Toki T; Sakuma T; Yamamoto T; Ito E; Oshimura M; Nakahata T; Saito MK
Haematologica; 2021 Feb; 106(2):635-640. PubMed ID: 32354872
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
